PostYou are now at: Home » Products » Chemicals » Organic Chemicals »

Letrozole CAS : 112809-51-5

Click image to view original image
Brand: Guangzhouquanao
型号: skype;Candice148722
规格: USP and SGS
Price: Negotiable
Min.Order:
Supply
Delivery: Shipment within 3 days since the date of payment
Address: China
Valid until: 2032-06-16
Updated on: 2015-01-14 17:25
Hits: 1594978
Enquiry
Company Detail
 
 
Details
    Letrozole is pyrrole type aromatase inhibitor, for the treatment of breast cancer.

  skype;Candice148722  

email: muscleman02@yccreate.com

tel:18102838257 

if you are interested in my products,pls contact me,thanks 


English Name:4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE; CGS-20267; FEMARA; LETROZOL; LetrozoleUsp28; Letrozole99%; CGS-20267, Femara; LETRAZOLE; letrozolex; Lelrozol; 1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazole-1-ylmethylene)bisbenzonitrile; 4,4'-[(1H-1,2,4-Triazole-1-yl)methylene]dibenzonitrile


CAS : 112809-51-5

Molecular Formula: C17H11N5 

Molecular Weight: 285.31

Appearance: White or almost white powder


Usage: 

1.Letrozole is a new generation aromatase inhibitor, is a synthetic derivative of benzyl triazole letrozole by inhibiting aromatase, estrogen levels decline, thereby eliminating the stimulating effect of estrogen on tumor growth.

2. treatment of postmenopausal advanced breast cancer (estrogen receptor, progesterone receptor positive or unknown receptor status), used for anti-estrogen therapy after failure of second-line treatment; 

3.line for locally advanced or spread of postmenopausal breast cancer; 

 for the received standard adjuvant tamoxifen therapy for five years after the extension of the adjuvant treatment of postmenopausal breast cancer patients; 

4 adjuvant therapy for hormone-positive early breast cancer patients.

Total: 0 [Show All]  Related Reviews
 
More »Our Others Products

[ ProductsSearch ]  [ Add To Favourite ]  [ Tell Friends ]  [ Print Content ]  [ Violation Report ]  [ Close Window ]